NEWS

Moderna announces first phase of human trials for mRNA shot to treat heart failure

Updated: January 13, 2023 at 7:57 pm EST  See Comments

Fri Jan 13, 2023 – 6:03 pm EST

(LifeSiteNews) – Moderna announced the first phase of human trials for an mRNA shot to treat those who have suffered from heart attacks amid mounting reports that the COVID mRNA shots themselves increase the risk of heart attacks.

“We are now in a super exciting program where we inject mRNA in people’s heart after a heart attack to grow back new blood vessels and re-vascularize the heart,” Moderna CEO Stéphane Bancel told Sky News in an October interview, adding, “It’s really like science fiction medicine.”

Moderna CEO Stéphane Bancel Announces New mRNA Shot to Treat Heart Failure Patients

“We are now in a super exciting program where we inject mRNA in people’s heart after a heart attack to grow back new blood vessels and re-vascularize the heart”https://t.co/kI3afoLU89 pic.twitter.com/zNw4rQN0Lv

— Chief Nerd (@TheChiefNerd) January 11, 2023

Moderna announced this week that the new mRNA treatment has been injected into the first trial participants, who have “stable heart failure,” to assess its safety and effects. The shot, mRNA-0184, encodes for relaxin, a hormone that causes changes in blood flow that are “potentially beneficial for heart failure patients.”

The

The remainder of this article is available in its entirety at LifeSite News

The views expressed in this news alert by the author do not directly represent that of The Official Street Preachers or its editors

Advertisement
Inspirational Finished Christian Pocket Knife - 3 Inch Blade
0 0 votes
Article Rating
Subscribe
Notify of
guest

0 Comments
Inline Feedbacks
View all comments
A Quick Note…

Already a subscriber? Login to remove advertisements. Not a subscriber? Join the Official Street Preachers and gain access to hundreds of presentations and exclusives that cover today's events and how they impact you, your life, and your soul. All while supporting independent Christian researchers trying to make a difference.